Received Jun 5, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | 1 | — | — |
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | 2 | — | — |
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | 3 | Z002520 | — |
No symptoms reported.; a patient who was inadvertently administered MMR-II instead of hepatitis B vaccine (manufacturer unspecified) on 05/28/2025.; this was the patient's third dose of MMR-II (first dose was administered on 06/2023 and second dose was administered on 07/2023; This spontaneous report was received from a pharmacist referring to a patient of unknown age and gender. The patient's medical history, historical drugs, concurrent conditions, and concomitant drugs were not reported. On an unknown date in June 2023 and July 2023, the patient was vaccinated with the first and second dose of Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II) (dose, strength, route of administration, lot#, and expiration date were not reported) for prophylaxis. On 28-MAY-2025, the patient was inadvertently administered Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II) (0.5 ml/ dose, lot#: Z002520, expiration date: 07-JAN-2027; route of administration was not reported) instead of hepatitis B vaccine (manufacturer unspecified) for prophylaxis (wrong product administered and extra dose administered). The vaccine was reconstituted with sterile diluent (MERCK STERILE DILUENT) (dose, strength, route of administration, lot#, and expiration date were not reported). No additional adverse events (AE) details were reported (no adverse event).
Merck sterile diluent